Coloplast expects its Kerecis wound-care unit to resume positive growth from January 1, 2027, after U.S. Medicare reimbursement changes severely hit sales in outpatient care. CFO Anders Lonning-Skovgaard told Reuters the outpatient business, which accounts for about 20%-30% of Kerecis sales, has "basically collapsed" since the payment changes took effect. The company is now shifting Kerecis sales efforts toward inpatient care, where reimbursement has been largely unaffected and which represents around 70%-80% of sales and is still growing at double-digit rates. Coloplast bought Icelandic fish-skin wound treatment maker KERECIS hf. for up to $1.3 billion in 2023 and has since written down 3 billion Danish crowns ($464.46 million) of goodwill tied to the acquisition. In the third quarter, Coloplast's Biologics business, which includes Kerecis, posted a 6% sales decline and a negative 5% EBIT margin. The company has also cut its growth assumptions for Kerecis this year and is reviewing investment priorities across the group to direct more resources to the United States.